Rockwell Medical shares surge 15.95% premarket after Q4 sales exceed estimates, gross margin improves to 22%, and positive cash flow.

Rockwell Medical (RMTI) surged 15.95% in premarket trading following the release of preliminary unaudited Q4 2025 financial results exceeding expectations. The company reported Q4 net sales of $18.6 million, surpassing analyst estimates of $16.55 million, with full-year revenue projected at $69.5 million (vs. $67.46M estimated). Key highlights included a 22% gross margin (up from 14% in Q3 2025), positive cash flow from operations ($2.3 million), and adjusted EBITDA positivity. Management emphasized operational efficiencies, cost reductions, and a strategic focus on revenue growth, profitability, and portfolio diversification in 2026. The results signaled progress toward profitability and long-term stability, bolstering investor confidence.